American Journal of Ophthalmology
Volume 149, Issue 6 , Pages 939-946.e1 , June 2010

Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated in the MARINA and ANCHOR Trials

  • Irene A. Barbazetto

      Affiliations

    • Vitreous Retina Macula Consultants of New York, New York, New York
    • ,
  • Namrata Saroj

      Affiliations

    • Genentech, Inc, South San Francisco, California
    • ,
  • Howard Shapiro

      Affiliations

    • Genentech, Inc, South San Francisco, California
    • ,
  • Pamela Wong

      Affiliations

    • Genentech, Inc, South San Francisco, California
    • ,
  • Allen C. Ho

      Affiliations

    • Mid Atlantic Retina and Wills Eye Institute, Philadelphia, Pennsylvania
    • ,
  • K. Bailey Freund

      Affiliations

    • Vitreous Retina Macula Consultants of New York, New York, New York
    • Corresponding Author InformationInquiries to K. Bailey Freund, Vitreous Retina Macula Consultants of New York, 460 Park Avenue, Fifth Floor, New York, NY 10022

,Accepted 5 January 2010.

References 

  1. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104:7–21
  2. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114:253–262
  3. Mukesh BN, Dimitrov PN, Leikin S, et al. Five-year incidence of age-related maculopathy: the Visual Impairment Project. Ophthalmology. 2004;111:1176–1182
  4. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol. 2003;121:519–526
  5. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997;115:741–747
  6. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degenerationunilateral extrafoveal choroidal neovascularization. Arch Ophthalmol. 1993;111:1189–1199
  7. Solomon SD, Jefferys JL, Hawkins BS, Bressler NM. Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. Arch Ophthalmol. 2007;125:1323–1330
  8. Pauleikhoff D, Radermacher M, Spital G, et al. Visual prognosis of second eyes in patients with unilateral late exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2002;240:539–542
  9. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005;112:533–539
  10. Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001;42:2237–2241
  11. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695–1715
  12. Neri P, Mariotti C, Mercanti L, Salvolini S, Giovannini A. Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). Int Ophthalmol. 2008;28:425–427
  13. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246:1379–1381
  14. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855–859
  15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444
  16. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65
  17. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
  18. Genentech Inc.. LUCENTIS® (ranibizumab injection) drug label. South San Franciso, CA: Genentech, Inc; 2007;
  19. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179–2182

 Supplemental Material available at AJO.com

PII: S0002-9394(10)00023-1

doi: 10.1016/j.ajo.2010.01.007

American Journal of Ophthalmology
Volume 149, Issue 6 , Pages 939-946.e1 , June 2010

Article Tools

* Image Usage & Resolution